Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pentobarbital
Drug ID BADD_D01726
Description A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Indications and Usage For the short-term treatment of insomnia.
Marketing Status approved; investigational; vet_approved
ATC Code N05CA01
DrugBank ID DB00312
KEGG ID D00499
MeSH ID D010424
PubChem ID 4737
TTD Drug ID D0F0YZ
NDC Product Code Not Available
UNII I4744080IR
Synonyms Pentobarbital | Pentobarbitone | Mebubarbital | Etaminal | Ethaminal | Sagatal | Nembutal | Pentobarbital Sodium | Pentobarbital, Monosodium Salt | Monosodium Salt Pentobarbital | Diabutal | Mebumal
Chemical Information
Molecular Formula C11H18N2O3
CAS Registry Number 57-33-0
SMILES CCCC(C)C1(C(=O)NC(=O)NC1=O)CC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation17.02.05.012; 19.06.02.001--
Alcohol problem19.07.06.003--Not Available
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Ataxia17.02.02.001; 08.01.02.004--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Completed suicide19.12.01.001; 08.04.01.010--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Depressed level of consciousness17.02.04.002--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Feeling abnormal08.01.09.014--Not Available
Generalised oedema14.05.06.007; 08.01.07.004--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatocellular injury09.01.07.008--Not Available
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Hypoventilation22.02.01.007--Not Available
Hypoxia22.02.02.003--
Injection site reaction12.07.03.015; 08.02.03.014--
Loss of consciousness17.02.04.004--Not Available
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages